Current:Home > Contact-usA new nasal spray to reverse fentanyl and other opioid overdoses gets FDA approval-LoTradeCoin
A new nasal spray to reverse fentanyl and other opioid overdoses gets FDA approval
View Date:2024-12-24 00:08:22
WASHINGTON — U.S. health regulators on Monday approved a new easy-to-use version of a medication to reverse overdoses caused by fentanyl and other opioids driving the nation's drug crisis.
Opvee is similar to naloxone, the life-saving drug that has been used for decades to quickly counter overdoses of heroin, fentanyl and prescription painkillers. Both work by blocking the effects of opioids in the brain, which can restore normal breathing and blood pressure in people who have recently overdosed.
The Food and Drug Administration endorsed Opvee, a nasal spray update of the drug nalmefene, which was first approved as an injection in the mid-1990s but later removed from the market due to low sales. Naloxone comes as both a nasal spray and injection.
It's not immediately clear how the new drug will be used differently compared to naloxone, and some experts see potential downsides to its longer-acting effect. The drug will be available via prescription and is approved for patients 12 and older.
In studies funded by the federal government, Opvee achieved similar recovery results to Narcan, the leading brand of naloxone nasal spray.
Opvee was developed by Opiant Pharmaceuticals, which was recently acquired by rival Indivior, maker of several medications for opioid addiction. Indivior expects to launch Opvee in October at the earliest.
As the opioid epidemic has shifted to fentanyl and other synthetic opioids, researchers in the pharmaceutical industry and the U.S. government saw a new role for the drug.
Because fentanyl stays in the body longer than heroin and other opioids, some people may require multiple doses of naloxone over several hours to fully reverse an overdose.
Scientists at the National Institutes of Health worked with pharmaceutical researchers on a nasal spray version of nalmefene that would quickly resuscitate users, while also protecting them from relapse. Testing and development was funded by more than $18 million in grants from the U.S. government's Biomedical Advanced Research and Development Authority and the NIH, which also helped design the studies.
"The whole aim of this was to have a medication that would last longer but also reach into the brain very rapidly," said Dr. Nora Volkow, director of the National Institute on Drug Abuse.
Still, some experts see potential downsides.
A side effect of all opioid reversal drugs is that they create intense withdrawal symptoms including nausea, diarrhea, muscle cramps and anxiety. With naloxone, those symptoms might last 30 to 40 minutes.
Dr. Lewis Nelson of Rutgers University says those problems can last six hours or more with nalmefene, requiring extra treatment and management by health professionals.
"The risk of long-lasting withdrawal is very real and we try to avoid it," said Nelson, an emergency medicine physician and former adviser to the FDA on opioids.
Nelson said it's easy enough to give a second or third dose of naloxone if it wears off.
"We're not suffering from a naloxone shortage where we need to use an alternative," he said. "We have plenty of it and it works perfectly well."
The FDA approval comes as drug overdose deaths inched up slightly last year after two big leaps during the pandemic. More than 109,000 fatal overdoses were recorded in 2022, according to the latest figures from the Centers for Disease Control and Prevention.
More than two-thirds of those deaths were linked to fentanyl and other synthetic opioids, which have largely replaced heroin and prescription opioids.
Naloxone has long been at the center of government efforts to fight the overdose crisis at the federal and local levels. Police, firefighters and other first responders routinely carry the drug. And officials in all 50 states have given orders to pharmacists to sell or dispense the drug without a prescription to anyone who wants it.
In the latest federal push, the FDA recently approved Narcan to be sold over the counter. The change will allow the new version of the drug to be stocked in grocery stores, vending machines and other retail locations. The nasal spray — which includes updated instructions for regular users — is expected to launch this summer. Emergent Biosolutions hasn't yet announced a price for the over-the-counter version.
Indivior said it is still considering what to charge for its drug. It will compete in the same market as naloxone, where most buyers are local governments and community groups that distribute to first responders and those at risk of overdose. Indivior has told investors that Opvee could eventually generate annual sales between $150 million to $250 million.
veryGood! (5741)
Related
- Full House's John Stamos Shares Message to Costar Dave Coulier Amid Cancer Battle
- Untangling the Many Lies Joran van der Sloot Told About the Murders of Natalee Holloway & Stephany Flores
- Opportunities for Financial Innovation: The Rise of Alpha Elite Capital (AEC) Corporate Management
- Macy's to shut down 150 'underproductive' store locations by 2026, company announces
- Blake Snell free agent rumors: Best fits for two-time Cy Young winner
- New York City medical school students to receive free tuition moving forward thanks to historic donation
- Debt, missed classes and anxiety: how climate-driven disasters hurt college students
- Preparing for early retirement? Here are 3 questions to ask before you do.
- Mike Tyson-Jake Paul: How to watch the fight, time, odds
- Cherry Starr, philanthropist wife of the late Green Bay Packers quarterback Bart Starr, dies at 89
Ranking
- Medical King recalls 222,000 adult bed assistance rails after one reported death
- Book excerpt: What Have We Here? by Billy Dee Williams
- Ariana Grande Addresses Media Attention Amid Ethan Slater Romance
- Tax refunds are higher so far this year, the IRS says. Here's the average refund amount.
- Jack Del Rio leaving Wisconsin’s staff after arrest on charge of operating vehicle while intoxicated
- Miranda Kerr Gives Birth to Baby No. 4, Her 3rd With Evan Spiegel
- Tennessee replaces Arizona as No. 1 seed in NCAA men's tournament Bracketology
- In New York, a Legal Debate Over the State’s New Green Amendment
Recommendation
-
LSU leads college football Week 11 Misery Index after College Football Playoff hopes go bust
-
How to make an ad memorable
-
Letter containing white powder sent to Donald Trump Jr.'s home
-
FDA warns against smartwatches, rings that claim to measure blood sugar without needles
-
A crowd of strangers brought 613 cakes and then set out to eat them
-
The rate of antidepressants prescribed to young people surged during the pandemic
-
Nebraska prosecutors to pursue death penalty in only one of two grisly small-town killings
-
Georgia Senate seeks to let voters decide sports betting in November